[News Space=Reporter seungwon lee] Samsung BioLogics (CEO John Lim) announced on the 4th that it recorded a cumulative order amount of KRW 5.5193 trillion based on public disclosure standards for the year, surpassing the previous year's annual order amount (KRW 5.4035 trillion) in just 10 months. This is the largest annual order amount since the company's founding.

Samsung BioLogics announced today that it has signed a contract manufacturing organization (CMO) increase contract worth approximately KRW 275.9 billion (USD 215 million) with a European pharmaceutical company.

This contract brings the total number of new and increased contracts signed this year to eight, based on public disclosure standards. Notably, the company continues its high growth by securing a series of large-scale orders from major global clients, starting with a record-breaking KRW 2 trillion contract in January and then an additional KRW 1.8 trillion contract with a U.S.-based pharmaceutical company in September.

Samsung BioLogics currently boasts 17 of the top 20 global pharmaceutical companies as clients. Backed by its core competitiveness—overwhelming production capacity, proven quality, and a proven track record—the company has surpassed $20 billion in cumulative orders since its founding.

Samsung Biologics is expanding its production capacity to proactively respond to the growing demand for biopharmaceuticals. Plant 5, an 180,000-liter production facility that integrates the best practices of Plants 1 through 4, began operations in April. This expansion gives Samsung Biologics a global production capacity of 784,000 liters.

In terms of quality competitiveness, the company has demonstrated a world-class quality system with a 99% batch success rate. As of October 2025, the company has received a total of 394 manufacturing approvals from major global regulatory agencies, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan. The number of approvals continues to increase each year, driven by expanded production capacity and increased orders.

John Lim, CEO of Samsung BioLogics, said, “This achievement is the fruition of customer trust and quality-centered management, and is a meaningful result achieved through close collaboration with global partners.” He added, “We will continue to strengthen the company’s growth momentum and further increase global customer satisfaction based on our world-class production competitiveness and rapid supply capabilities.”